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On the basis of the outlined in vivo 
studies, the current study by Ren and co-
workers,1 and the established vascular 
renal effects of adenosine,10 a concept 
could be envisioned in which small pertur-
bations of the TGF signal from the operat-
ing point trigger parallel changes in local 
adenosine concentrations that induce pri-
marily aff erent arteriolar vasoconstriction 
via adenosine A1 receptors and eff erent 
vasoconstriction due to passive interac-
tions with RA (see above) and/or due to 
some coactivation of adenosine A1 recep-
tors on the eff erent arteriole such that PGC 
remains unchanged. In comparison, more 
excessive TGF signals trigger larger local 
adenosine concentrations that in addition 
induce a vasodilating influence on the 
eff erent arteriole via adenosine A2 recep-
tors, which attenuates or prevents a further 
rise in RE and thus lowers PGC (Figure 1).
In summary, the basal conditions, the 
co-response of the afferent arteriole, 
and the strength of TGF stimuli applied 
may dictate the net magnitude and even 
the direction of the efferent arteriolar 
response. Th e study by Ren and co-work-
ers1 has defi ned an important infl uence, 
which tends to reduce RE during TGF 
activation, and this appears to be another 
important eff ect of local adenosine. From 
a teleological standpoint, a TGF-induced 
adenosine-mediated eff erent vasodilatory 
infl uence would be appealing especially in 
deep nephrons, where the postglomeru-
lar blood fl ow is nutritive for the medulla 
and thus consistent with a proposed role 
of adenosine in metabolic control of kid-
ney function.10
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Diabetes: Caught in the Akt?
PM Price1
One complication of diabetes is a pronounced renal cellular 
hypertrophy, inevitably resulting in chronic fibrotic changes. Chuang 
and colleagues demonstrate that hypertrophy in vitro is dependent 
on an increased phosphoinositide 3-kinase (PI3K) activity and is 
correlated with increased levels of p21WAF1/Cip1, a cell-cycle regulator 
that was previously associated with renal fibrosis and sclerosis from 
nondiabetic causes.
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Th e response of hypertrophy occurs in 
organs, such as heart, lungs, and kid-
neys, usually in reaction to a demand for 
increased work load. This reaction, in 
which there is an increase in total cell vol-
ume without a similar increase in total cell 
number, has been suggested in older liter-
ature to be maladaptive.1 Renal hypertro-
phy is found in several diff erent disorders 
and is associated with a progressive loss of 
kidney function and eventual glomerular 
and tubulointerstitial fi brosis. Although 
hypertrophy may be accompanied or 
preceded by a period of hyperplasia,2–4 
chronic fi brotic changes in the kidney are 
preceded by hypertrophic growth.5 Several 
in vivo models, such as the rodent models 
of streptozotocin-induced diabetes and 
renal ablation, mimic clinically observed 
kidney and systemic changes. A similar 
hypertrophic response was also observed 
in vitro when kidney cells were cultured in 
high-glucose-containing medium.6–8
The commitment to hypertrophic 
growth by kidney cells in reaction to 
diabetes or ablation has recently been 
approached by the use of gene knockout 
studies. Early evidence had shown that 
proteins associated with cell-cycle regu-
lation and inhibition were increased in 
the kidney aft er both acute and chronic 
stress,9,10 and that these inhibitors, trans-
duced into kidney proximal tubular 
cells, caused hypertrophy.11 In knock-
out models of one of these proteins, the 
p21 cyclin-dependent kinase inhibitor, 
hypertrophy, glomerulosclerosis, and 
interstitial fi brosis did not develop aft er 
partial renal ablation,4 and glomerular 
hypertrophy did not occur in streptozo-
tocin-treated mice.12 Th us it may be con-
cluded that the hyperplastic increase in 
kidney cells observed in these models was 
not detrimental, but that hypertrophic 
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growth was maladaptive. Preventive 
intervention in the p21-induced hyper-
trophic response may be possible if this 
pathway can be further elucidated and 
potential targets identifi ed.
Chuang et al.13 (this issue), using 
LLC-PK1 cells, a porcine kidney proxi-
mal tubule-derived cell line, show that 
the hypertrophic response to culture in 
high-glucose medium is dependent on 
an increase in phosphoinositide 3-kinase 
(PI3K) activity, and as in other studies, 
hypertrophy was also associated with 
elevated p21. Inhibition of PI3K not only 
ameliorated hypertrophy but also lowered 
p21 levels. So can these two proteins, one 
an inhibitor of cell-cycle kinases, and the 
other a kinase activator of the oncoprotein 
Akt, have a common pathway that ulti-
mately results in cellular hypertrophy?
More than 500 protein kinases are 
encoded by the human genome. The 
functions of many are known, and these 
enzymes control protein expression 
and degradation and protein function, 
localization, and interactions. These 
kinases direct the function of the cell 
and, ultimately, its life and death. It is 
not surprising, therefore, that the fate of 
cells in the kidney, and the fate of the 
kidney as an organ, are also controlled 
by protein kinases.
The p21 protein is a member of a 
family of proteins that inhibit the cyc-
lin-dependent kinases responsible for 
progression through DNA synthesis and 
mitosis during the cell cycle. It is con-
stitutively expressed at low levels and is 
usually localized to the nucleus. Its inhib-
itory activity and the fi nding that p21 is 
highly upregulated aft er DNA damage 
and other types of cellular stress led to the 
proposal that these inhibitors control the 
cell cycle, either allowing or inhibiting 
cell replication. Th e ‘regulation’ imposed 
on the cell cycle by p21 makes it possible 
for cells under various types of stress, 
many of which elevate p21, to interrupt 
replication and division until the stress 
is relieved and p21 returns to lower lev-
els. On the other hand, the upregulation 
of p21 could work against this system 
unless the load is reduced. Th e inability 
to undergo cell division coupled with the 
stress imposed on an organ by increased 
work load may result in increased size by 
hypertrophy. Th is reaction is likely to be 
regulated by both the cell type and the 
extent of stress encountered.
PI3K promotes cell-cycle activity by 
several diff erent pathways, including inhi-
bition of proteins that repress cell division 
and activation of proteins that stimulate 
replication. Aft er activation, PI3K phos-
phorylates a phosphoinositide intermedi-
ate, allowing Akt, a downstream eff ector 
of PI3K, to be recruited and activated. 
Although many pathways are initiated 
by PI3K, the Akt pathway in particular is 
relevant to cell growth. As was fi rst noted 
in Drosophila,14 overexpression of Dakt1 
(the fl y homologue of human Akt) caused 
cellular and organ hypertrophy, whereas 
disruption of the Dakt1 gene caused a sig-
nifi cant decrease in size. Th is eff ect was 
also noted in knockout and overexpress-
ing transgenic mice (cited by Shiojima et 
al.15), even though the Akt gene in higher 
vertebrates is redundant (there are three 
Akt genes), and the eff ect of loss of one 
gene can be at least partially compensated 
for by the other genes.
Chuang et al.13 correlated the activa-
tion of PI3K, Akt, and elevated p21 with 
hypertrophic growth of cells in high-
glucose medium. Hypertrophy in their 
study was measured by an increased pro-
tein–DNA ratio. Inhibition of PI3K, either 
by the drug LY294002 or by transfection 
of a dominant-negative plasmid that 
inhibits the regulatory subunit (p85) of 
PI3K, lessened both hypertrophy and the 
level of p21. Th e increase in p21 protein 
was probably because of transcriptional 
upregulation, since the measured half-life 
of both p21 protein and mRNA actually 
decreased in cells grown in high-glucose 
medium, while the activity of the p21 pro-
moter increased severalfold in high-glu-
cose medium. Whether the hypertrophic 
growth was because of the eff ect of PI3K 
on p21 levels or was independent of p21 
was not investigated.
It is possible to speculate, because 
of Chuang and colleagues’ finding of 
transcriptional regulation of the p21 
promoter,13 that PI3K either directly or 
indirectly activated p21 promoter-inter-
acting transcription factors, which were 
responsible for the increased level of p21 
protein, resulting in hypertrophy. PI3K 
and Akt were previously shown to acti-
vate several transcription factors,16 but 
whether these or other undetermined 
PI3K-dependent proteins can modu-
late p21 promoter activity remains to 
be determined. On the other hand, Akt 
was shown in other studies to phospho-
rylate p21 at a region that dissociated it 
from its normally inhibitory binding of 
PCNA, a DNA polymerase subunit neces-
sary for DNA synthesis, while at the same 
time promoting p21 translocation from 
the nucleus into the cytoplasm.17 Th ese 
results demonstrate that the p21 and PI3K 
pathways intersect in at least two ways: 
fi rst, by PI3K-dependent induction of p21 
transcription, and second, by direct inter-
action between Akt and p21. Although 
these intersections may be suffi  cient to 
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Figure 1 | Interactions of Akt, p21, and P13K after high glucose stress. In diabetes (or in 
the high-glucose in vitro model used by Chuang et al.13), phosphoinositide 3-kinase (PI3K) 
is upregulated, resulting in elevated levels of Akt and p21. Growth is stimulated by PI3K but 
could also be stimulated by other types of renal stress. Several of the possible mechanisms for 
hypertrophic growth under these conditions are discussed in this Commentary. First, persistent 
growth stimulation and elevated cell-cycle inhibitor levels could result in hypertrophy rather 
than hyperplasia. Second, Akt-dependent p21 phosphorylation could sequester p21 in the 
cytoplasm, where it may also stimulate growth. Third, p21 by itself is known to activate pathways of 
senescence, which may lead to fibrotic changes associated with aging.
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explain the dependence of hypertrophy 
on PI3K, p21 has roles beyond that of 
cell-cycle inhibition depending on the 
cellular stress and environment. One of 
the original descriptions of p21 was as 
an inducer of cellular senescence,18 and 
p21 deletion was shown to prolong the 
lifespan of telomerase-defi cient cells and 
mice,19 a condition associated with short-
ened lifespan in humans and in mice. 
Coincidently, p21 but not p16 (another 
cyclin-dependent inhibitor) was found 
to be involved in telomere shortening-
induced senescence of human cells,20 
and transduction of p21 but not of p16 
caused hypertrophy in renal proximal 
tubule cells.11 Perhaps the consequences 
of renal hypertrophy and the fibrotic 
changes associated with aging are both 
controlled by the same PI3K/Akt/p21 
pathways. Th ese possibilities should be 
fruitful areas for future investigations.
In summary (Figure 1), both p21 and 
the PI3K/Akt pathways have been shown 
to be associated with cellular and organ 
hypertrophy. Th e work of Chuang et al.13 
reiterates this concept and at the same 
time shows that these pathways may be 
mutually interdependent. More work is 
needed to support these interactions and 
to elucidate fully the pathway of hyper-
trophy. At the same time, however, this 
work has pointed out possible interven-
tion strategies, by PI3K/Akt inhibition, to 
ameliorate hypertrophy.
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Membranous nephropathy: When 
and how to treat
KN Lai1
The treatment of idiopathic membranous nephropathy is heavily 
debated because of wide variation in outcome. A rational treatment 
strategy is needed to appropriately administer conservative treatment 
to the low-risk group but immunosuppressive therapy to those with 
medium or high risk of renal deterioration. Currently, combinations 
of steroids with alkylating agents are best studied. Newer forms of 
immunosuppressive treatment are currently under study. 
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Idiopathic membranous nephropathy 
(IMN) is a common cause of the nephrotic 
syndrome in adult patients. Th e treatment 
of patients with IMN has been a regular 
theme for debate. Today, once the diagno-
sis is made, symptomatic management for 
proteinuria and hypertension is mandated 
in almost all patients. Th e impact of these 
treatments alone on the natural history is 
expected to be positive but is diffi  cult to 
delineate distinctly. Th is wide variation 
in outcome is one of the factors that have 
led metaanalysis and systematic reviews of 
this disease to reach varying conclusions 
about the impact of immunosuppressive 
treatment on patient and renal survival 
and on remission rate of proteinuria.
Reports of the natural history of IMN 
are divergent and thus have set the stage 
for heavy disputes on the use of immuno-
suppressive therapy. Th e spectrum varies 
from a relatively benign course of 65% 
spontaneous remission of proteinuria and 
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